AntiCancer PDOX Reaches Series A Financing Target, Appoints Board
June 01, 2017 16:24 ET
|
AntiCancer PDOX, Inc.
CHICAGO, June 01, 2017 (GLOBE NEWSWIRE) -- ASCO 2017 -- AntiCancer PDOX, Inc. announced today that it has reached its original Series A financing target and appointed its Board of...
Fate Therapeutics Announces Preclinical Data Highlighting Persistent Effector Function of Allogeneic Natural Killer Cell Cancer Immunotherapy
May 16, 2016 08:01 ET
|
Fate Therapeutics, Inc.
Adaptive NK Cell Therapy Advancing Toward First-in-Human Clinical Trial in Collaboration with University of Minnesota Program to be Presented Today at Innate Killer Summit 2016 SAN DIEGO, May 16,...